ACE2-Expressing HER Cells for Scalable SARS-CoV Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing SARS-CoV in cell culture systems face limitations due to low yields, requiring serum and solid support, and are not human cell-based, making large-scale production economically unattractive and inefficient.
Innovation Solution
Utilizing primary human retina cells (HER cells) expressing the human ACE2 protein, which supports high and reproducible SARS-CoV yields, allowing for suspension growth and serum-free medium use, suitable for large-scale production and replication of various SARS-CoV isolates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If Vero or Vero E6 cells are used for SARS-CoV production, then virus replication is supported, but yields are low and purification becomes difficult due to serum requirement and solid support adherence
Solution Approach 1:
The patent changes the growth parameters of the cell system by using human embryonic retinoblast cells that can be cultured in suspension without serum requirement. This parameter change enables both high virus yield and easy purification, as the cells detach naturally and can be removed by centrifugation, eliminating the complex purification steps required when using adherent Vero cells.
Solution Approach 2:
The patent uses human embryonic retinoblast cells as a alternative model system that copies the essential function of supporting SARS-CoV replication while avoiding the drawbacks of Vero cells. The human cells provide a more physiologically relevant environment that naturally supports high-level virus production without the purification complications.
2Productivity
If Vero or Vero E6 cells are used for SARS-CoV production, then virus replication is supported, but large-scale production becomes laborious and economically unattractive
Solution Approach 1:
The patent changes the operational parameters by using suspension-adapted human embryonic retinoblast cells that can be cultured in large-scale bioreactors without requiring solid support adherence. This enables automated, scalable production with simple centrifugation for cell removal, making large-scale production economically attractive and operationally straightforward.
3Productivity
If non-human cells are used for SARS-CoV production, then virus replication is supported, but human cell-based production is needed for optimal vaccine and therapeutic development
Solution Approach 1:
The patent uses human embryonic retinoblast cells as a human cell-based system that copies the essential function of supporting SARS-CoV replication. This provides both the physiological relevance of human cells and the production efficiency needed for vaccine and therapeutic development, eliminating the need to use non-human Vero cells.
4Productivity
If cells are adapted for suspension growth, then large-scale production becomes feasible, but achieving reproducible suspension behavior is difficult
Solution Approach 1:
The patent uses human embryonic retinoblast cells that have been specifically adapted to suspension culture conditions. These cells naturally exhibit reproducible suspension behavior with consistent growth characteristics, enabling reliable large-scale production. The cells maintain stable suspension adaptation across passages, providing both scalability and reproducibility.
Data Source
AI summary
The invention relates to the production of coronaviruses. In particular, the invention relates to methods for producing SARS-CoV by using cells expressing a functional SARS-CoV receptor.